Negative / Null Result ReportOpen accessMedicine· cited by 21

GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential

Osama Sobhi Moaket; Sarah Eyad Obaid; Fawaz Eyad Obaid; Yusuf Abdulkarim Shakeeb; Samir Mohammed Elsharief; Afrin Tania; Radwan Darwish; Alexandra E. Butler · 2025 · International Journal of Molecular Sciences

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and depression, are marked by progressive neuronal dysfunction and loss, yet current treatments remain largely symptomatic with limited disease-modifying efficacy. Glucagon-like peptide-1 (GLP-1), an incretin hormone traditionally associated with metabolic regulation, has emerged as a promising neuroprotective agent. Its receptor, GLP-1R, is expressed in key brain regions implicated in cognition, emotion, and motor control, including the hippocampus, frontal cortex, and substantia nigra. GLP-1R a

Abstract by Osama Sobhi Moaket; Sarah Eyad Obaid; Fawaz Eyad Obaid; Yusuf Abdulkarim Shakeeb; Samir Mohammed Elsharief; Afrin Tania; Radwan Darwish; Alexandra E. Butler, International Journal of Molecular Sciences (2025) — licensed CC BY 4.0.

Read the full paper (open access)